PlainPharmaWatch

CMS Open Payments · Program Year 2024

Deciphera Pharmaceuticals Inc.

Deciphera Pharmaceuticals Inc. reported $21,909,924.45 across General Payments, Research, and Ownership to 3,335 physicians and teaching hospitals across 4,910 transactions.

See the rankings → How this is sourced
$21.9M
All-tracks total
4,910
Transactions
3,335
Recipients
−$45.0K
General Payments vs PY2023

Deciphera Pharmaceuticals Inc. reported $21,909,924.45 across all CMS Open Payments tracks (General + Research + Ownership) to 3,335 physicians and teaching hospitals in Program Year 2024 - ranking #87 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $602,665.40, averaging $6.6K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer deciphera-pharmaceuticals-inc Deciphera Pharmaceuticals Inc.

$21.9M · #87/1,925 · 0.2% industry · PY2024

  • TOT $21.9M
  • RANK #87
  • SHARE 0.2%
  • TXN 4,910
  • RCP 3,335
  • CAT 5
  • GEN $602.7K
  • ΔGEN −$45.0K
  • TOP1 5.1%
  • PY 2024

Volume peers

Nearest volume peer: Alphatec Spine, Inc ($22.3M)

Bausch Health US, LLC$22.5MAlphatec Spine, Inc$22.3MDeciphera Pharmaceuticals In…$21.9MAadi Bioscience, Inc.$21.5MSage Therapeutics, Inc.$20.9M
All-tracks payment totals near Deciphera Pharmaceuticals Inc. (CMS Open Payments PY2024)

Deciphera Pharmaceuticals Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Deciphera Pharmaceuticals Inc.'s CMS-reported General Payments decreased by $45.0K (−6.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: DECIPHERA PHARMACEUTICALS INC.PY2023: DECIPHERA PHARMACEUTICALS INC.PY2024: Deciphera Pharmaceuticals Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$647.6KPY2024$602.7K
PY2023
$647,621.37
PY2024
$602,665.40

What the Data Shows for Deciphera Pharmaceuticals Inc.

$21,909,924.45: that is what Deciphera Pharmaceuticals Inc. reported in payments to 3,335 physicians and teaching hospitals during Program Year 2024, spread across 4,910 transactions ($4.5K per transaction, $6.6K per recipient). The company sits at rank #87 of 1,925, representing 0.2% of all industry payments reported nationwide for the year.

"Honoraria" leads the 5-category general-payment breakdown below at $285.6K (47.4% of General Payments, 103 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Deciphera Pharmaceuticals Inc. made 5 types of general payments. "Honoraria" is the largest category at $285.6K, 47.4% of General Payments.

Deciphera Pharmaceuticals Inc. reports 5 general-payment categories - the top three are Honoraria (47.4%), Food and Beverage (15.1%), and Compensation for Services Other Than Consulting (15.0%). The remaining 2 categories make up 22.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Deciphera Pharmaceuticals Inc. divides its payments

Ranked by total dollars reported per category

1. Honoraria$285.6K2. Food and Beverage$90.9K3. Compensation for Services…$90.3K4. Travel and Lodging$77.5K5. Consulting Fee$58.3K
Payment Type Amount Transactions
Honoraria $285.6K 103
Food and Beverage $90.9K 2,922
Compensation for Services Other Than Consulting $90.3K 44
Travel and Lodging $77.5K 230
Consulting Fee $58.3K 36

Recipient Concentration in General Payments

The five largest recipient relationships account for $117,964.34 (19.6%) of $602,665.40 in this company's General Payments records across 2,119 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Deciphera Pharmaceuticals Inc.

The five named recipients with the highest reported General Payments from this company

Mark Agulnik$31.0KEdward Benz$30.6KArlene Hady Ortega$21.2KCiara M Kelly$18.0KDale Shepard$17.1K
  1. 1

    Mark Agulnik

    $31,035.83 across 30 reported transactions

  2. 2

    Edward Benz

    $30,620.02 across 3 reported transactions

  3. 3

    Arlene Hady Ortega

    $21,234.95 across 31 reported transactions

  4. 4

    Ciara M Kelly

    $17,984.55 across 14 reported transactions

  5. 5

    Dale Shepard

    $17,088.99 across 24 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Deciphera Pharmaceuticals Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Deciphera Pharmaceuticals Inc..

Radius Health, Inc.

HHI 162

Kuros Biosciences USA, Inc

HHI 162

Merz Pharmaceuticals, LLC

HHI 162

Fortis Surgical, LLC

HHI 163

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Deciphera Pharmaceuticals Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Deciphera Pharmaceuticals Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.